CDXS - Codexis, Inc.
After hours:
| Previous Close | 2.4800 |
| Open | 2.5100 |
| Bid | 2.3900 x 4000 |
| Ask | 2.6300 x 1200 |
| Day's Range | 2.4150 - 2.5300 |
| 52 Week Range | 2.4150 - 13.0300 |
| Volume | |
| Avg. Volume | 720,604 |
| Market Cap | 164.916M |
| Beta (5Y Monthly) | 1.64 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7200 |
| Earnings Date | Aug 02, 2023 - Aug 07, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.14 |
GlobeNewswireCodexis to Participate in Jefferies Healthcare Conference
REDWOOD CITY, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York. Management will participate in a fireside chat on Wednesday, June 7, 2023, at 1:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 9
- GlobeNewswire
Codexis Unveils ECO Synthesis™ Platform for Large-Scale RNAi Therapeutics Production at TIDES USA
--Proprietary technology being developed to address sustainability and scalability challenges of oligonucleotide manufacturing--REDWOOD CITY, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the unveiling of its Enzyme-Catalyzed Oligonucleotide (ECO) Synthesis™ technology, a proprietary new synthesis platform being developed for manufacturing RNA oligonucleotide therapeutics at scale. The ECO Synthesis™ technology was un
- GlobeNewswire
Codexis Announces New Employment Inducement Grants
REDWOOD CITY, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the approval of equity grants to five new employees as approved by the Compensation Committee of Codexis’s Board of Directors. The newly hired employees received equity awards consisting of an aggregate of (i) options to purchase 56,773 shares of Codexis common stock and (ii) restricted stock units (RSUs) for 35,037 shares of Codexis common stock as inducemen
ZacksCodexis (CDXS) Reports Q1 Loss, Lags Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of -17.24% and 11.34%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Codexis Reports First Quarter 2023 Financial Results
CDX-7108 Clinical Development Program Remains on Track Estimated Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Reiterates 2023 Total Revenue Guidance with Adjustments to Product vs. R&D Revenue Mix and Range on Gross Margin REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the first quarter ended March 31, 2023, and provided a business update. “We had a pro
ZacksWill Alimera Sciences (ALIM) Report Negative Q1 Earnings? What You Should Know
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Simply Wall St.What Is Codexis, Inc.'s (NASDAQ:CDXS) Share Price Doing?
Codexis, Inc. ( NASDAQ:CDXS ), is not the largest company out there, but it received a lot of attention from a...
ZacksCodexis (CDXS) Expected to Beat Earnings Estimates: Should You Buy?
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire
Codexis to Report First Quarter 2023 Financial Results on May 4
REDWOOD CITY, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of market. The Company will not be conducting a conference call in conjunction with this financial results release. About Codexis Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to
- GlobeNewswire
Codexis Announces RNA Therapeutics Manufacturing Workshop at TIDES USA
REDWOOD CITY, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it will host a pre-conference workshop highlighting the role of an enzymatic approach to support RNA-based therapeutics manufacturing at the TIDES USA annual meeting being held May 7-10, 2023, in San Diego, CA. The workshop will be held live and virtually on Sunday, May 7, 2023. Ribonucleic acid (RNA) as a therapeutic modality has gained tremendous traction
- GlobeNewswire
Codexis Announces Decision of Patrick Yang, PhD, Not to Seek Re-Election to Board of Directors
REDWOOD CITY, Calif., April 04, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that Patrick Yang, PhD, will not seek re-election to the Codexis Board of Directors. Dr. Yang joined the Board in 2014 and served as the Chair of the Nominating and Corporate Governance Committee. “It has been a privilege to have Pat on the Codexis Board. His expertise in technical operations and manufacturing has been of tremendous value to the company,” s
- Simply Wall St.
Codexis, Inc.'s (NASDAQ:CDXS) Intrinsic Value Is Potentially 24% Below Its Share Price
Key Insights The projected fair value for Codexis is US$2.93 based on 2 Stage Free Cash Flow to Equity Codexis' US$3.88...
GlobeNewswireCodexis to Participate in Cowen 43rd Annual Health Care Conference
REDWOOD CITY, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will participate in both a panel discussion and a fireside chat at the Cowen 43rd Annual Health Care Conference, being held March 6-8, 2023, in Boston, Massachusetts. Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Codexis, will participate in a panel discussion titled, “SynBio & AI Driven Drug Discovery,” taking place on Mo
- Simply Wall St.
These Analysts Think Codexis, Inc.'s (NASDAQ:CDXS) Sales Are Under Threat
One thing we could say about the analysts on Codexis, Inc. ( NASDAQ:CDXS ) - they aren't optimistic, having just made a...
ZacksCodexis (CDXS) Reports Q4 Loss, Tops Revenue Estimates
Codexis (CDXS) delivered earnings and revenue surprises of 17.39% and 4.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Codexis Reports Fourth Quarter and Fiscal Year 2022 Financial Results
Biotherapeutics Application of CodeEvolver® Validated by Recent Data Supporting the Potential for Three Upcoming Investigational New Drug Applications Cash Runway Through End of 2024 Funds Important Upcoming Milestones Company Provides 2023 Revenue Guidance REDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2022 and provided a busine
- GlobeNewswire
Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency
Interim Data from Phase 1 Proof-of-Concept Arm Indicates CDX-7108 Improves Lipid AbsorptionREDWOOD CITY, Calif., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, and Nestlé Health Science, a leader in the science of nutrition, today announced interim results from a Phase 1 study to investigate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CDX-7108. CDX-7108 is a lipase variant specifically engineered to overcome the
- GlobeNewswire
Codexis Announces Several Key Presentations from its Gene Therapy Programs at 19th Annual WORLDSymposium™
REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today highlights several key presentations from its gene therapy programs from 19th Annual WORLDSymposium™, taking place from February 22-26, 2023, in Orlando, Florida. Notably, preclinical data in Fabry disease using its engineered transgene is being presented by its partner Takeda Pharmaceutical Company Limited (Takeda). This program is part of Codexis’ Strategic Collabor
- GlobeNewswire
Codexis to Report Fourth Quarter and Fiscal Year 2022 Financial Results on February 23
REDWOOD CITY, Calif., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2022 on Thursday, February 23, 2023, following the close of market. Codexis management will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Code
- Simply Wall St.
Codexis (NASDAQ:CDXS) shareholders have endured a 68% loss from investing in the stock a year ago
Over the last month the Codexis, Inc. ( NASDAQ:CDXS ) has been much stronger than before, rebounding by 41%. But that's...
- GlobeNewswire
Codexis Announces Appointment of Sri Ryali as Chief Financial Officer
REDWOOD CITY, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Sri Ryali as Chief Financial Officer effective immediately. Mr. Ryali brings 20 years of finance and commercial experience in life sciences to Codexis. In this role, Mr. Ryali will lead all aspects of the Company’s financial operations and will report directly to Dr. Stephen Dilly, President and Chief Executive Officer of Codexis. “I am ex
- GlobeNewswire
Codexis Announces Appointment of H. Stewart Parker to Board of Directors
REDWOOD CITY, Calif., Dec. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of H. Stewart Parker to its Board of Directors. “Stewart’s deep expertise in gene therapy and demonstrated track record of executive leadership within the biopharmaceutical industry make her a compelling addition as we seek to continue to strengthen the diversity of our Board with a breadth of professional experience, educational background,
- Simply Wall St.
Here's Why We're Not At All Concerned With Codexis' (NASDAQ:CDXS) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
- GlobeNewswire
Codexis Provides Update on Prioritized Corporate Strategy
REDWOOD CITY, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced an update on the Company’s ongoing plan to prioritize its time and resources on areas where the Company believes it has the strongest commercial opportunity and greatest probability of success. As part of this plan, the Company has decided to discontinue investment in certain internal development programs, expand investment in high potential development prog
